Linperlisib for relapsed or refractory T-LGLL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL).
- You have tried at least one standard treatment and it didn't work or you couldn't tolerate it.
- Your disease is causing problems like low blood counts, need for blood transfusions, a growing spleen, or severe symptoms.
- You are generally able to care for yourself (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
This trial tests a new targeted therapy (linperlisib) combined with rituximab, an existing antibody drug, for people with a slow-growing type of non-Hodgkin lymphoma that has come back or not responded to previous treatments. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests a combination of two drugs, Linperlisib and Chidamide, for people with peripheral T-cell lymphoma that has come back or not improved after at least one previous treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
Hear when a new Relapsed/Refractory Large Granular T Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.